Neurol. praxi. 2008;9(5):300-304

Neurologické projevy u mnohočetného myelomu

prof. MUDr. Zdeněk Ambler, DrSc.
Neonatologické oddělení, FN a LF UK, Plzeň

Neurologická symptomatika při diagnostice myelomu bývá nejčastěji míšní nebo radikulární v důsledku komprese z vertebrálních lézí. Častější komplikace jsou až v průběhu léčby. Nežádoucí neurologické projevy po transplantaci krvetvorných buněk nejsou příliš časté, může vzniknout metabolická encefalopatie, ale i různé infekce nebo cerebrovaskulární komplikace. Polyneuropatie v přímé souvislosti s myelomem jsou vzácné a často multifaktoriální. Závažné jsou toxické polyneuropatie po thalidomidu a bortezomibu. Jsou převážně senzitivní, s častými neuropatickými bolestmi. Základem je časná detekce a podle kvantifikace případné snížení dávek event. i přerušení medikace. Terapie toxických polyneuropatií je pouze symptomatická a hlavní význam má léčba neuropatických bolestí adjuvantními analgetiky.

Keywords: Klíčová slova: toxické polyneuropatie, mnohočetný myelom, thalidomid, bortezomib, neurotoxicita, neuropatická bolest, adjuvantní analgetika.

Published: November 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ambler Z. Neurologické projevy u mnohočetného myelomu. Neurol. praxi. 2008;9(5):300-304.
Download citation

References

  1. Adam Z, Bačovský J, Flochová E, et al. Diagnostika a léčba mnohočetného myelomu. Transfuze a hematologie dnes 2005; 1 Suppl. 1: 3-50.
  2. Adam Z, Bednařík J, Neunauer J, et al. Mnohočetný myelom a diferenciální diagnostika bolestí páteře. Doporučení České myelomové skupiny pro včasné vyslovení podezření na mnohočetný myelom a pro včasnou diagnostiku této choroby Prakt. Lékáren. 2006; 86: 396-410.
  3. Ambler Z. Polyneuropatie u mnohočetného myelomu. Farmakoterapie 2008; 4: 91-97.
  4. Apfel SC, Zochodne DW. Thalidomide neuropathy: Too much or too long? Neurology 2004; 62: 2158-2159. Go to original source... Go to PubMed...
  5. Badros A, Goloubeva O, Dalal JS, et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 2007; 110: 1042-1048. Go to original source... Go to PubMed...
  6. Gordon JN, Goggin PM. Thalidomide and its derivatives: emerging from the wilderness. Postgrad Med J 2003; 79: 127-132. Go to original source... Go to PubMed...
  7. Grassi MP, Clerici F, Perin C, et al. Light chain deposition disease neuropathy resembling amyloid neuropathy in a multiple myeloma patient. Ital J Neurol Sci 1998; 19: 229-233. Go to original source... Go to PubMed...
  8. Gupta S, Pagliuca A, Devereux S, et al. Life-threatening motor neurotoxicity in association with bortezomib. Haematologica 2006; 91: 1001. Go to PubMed...
  9. Huang HQ, Brady MF, Cella D, Fleming G. Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer 2007; 17: 387-393. Go to original source... Go to PubMed...
  10. Chaudhry V, Cornblath DR, Corse A, et al. Thalidomide-induced neuropathy. Neurology 2002; 59; 1872-1875. Go to original source... Go to PubMed...
  11. Isoardo G, Bergui M, Durelli L, et al. Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features. Acta Neurol Scand 2004; 109: 188-193. Go to original source... Go to PubMed...
  12. Lozeron P, Adams D. Monoclonal gammopathy and neuropathy. Curr Opin Neurol 2007; 20: 536-541. Go to original source... Go to PubMed...
  13. Miguel JS, Bladé J, Boccadoro M, et al. A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist 2006; 11: 51-61. Go to original source... Go to PubMed...
  14. Mileshkin L, Stark R, Day B, et al. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring J Clin Oncol 2006; 24: 4507-4514. Go to original source... Go to PubMed...
  15. Nieuwenhuizen L, Biesma DH. Central nervous system myelomatosis: review of the literature. Eur J Haematol 2008; 80: 1-9.
  16. Palumbo A, Facon T, Sonneveld P, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood 2008; 111: 3968-3977. Go to original source... Go to PubMed...
  17. Pollard JD, Young GAR. Neurology and the bone marrow. J Neurol Neurosurg Psychiatry 1997; 63; 706-717. Go to original source... Go to PubMed...
  18. Popat R, Oakervee HE, Hallam S, et al. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up. Br J Haematol 2008; 141: 512-516. Go to original source... Go to PubMed...
  19. Prince HM, Schenkel B, Mileshkin L. An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma. Leukemia & Lymphoma 2007; 48: 46-55. Go to original source... Go to PubMed...
  20. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006; 24: 3113-3120. Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.